Cerebrolysin Dosage Protocol

The CARS-2013 trial (NCT01215708) enrolled 208 patients with acute ischemic stroke and delivered Cerebrolysin 30 mL intravenously once daily for 10 consecutive days beginning within 72 hours of symptom onset, documenting a statistically significant improvement on the 90-day modified Rankin Scale versus placebo [1]. Cerebrolysin is a proteolytic peptide mixture of free amino acids and low-molecular-weight neuropeptide fragments derived from purified porcine brain tissue, standardized to approximately 215.2 mg of peptide per milliliter and delivered exclusively by parenteral routes because no oral bioavailability has been demonstrated in humans [2]. Reported protocols in the published literature cluster around fixed daily volumes of 10 mL, 20 mL, or 30 mL administered as intravenous infusions in saline or as slow intramuscular injections over 10 to 30 consecutive treatment days, typically repeated in 2 to 4 courses per year for chronic indications [1,2,3].

How Cerebrolysin Works: Mechanism of Action

In short: Cerebrolysin is a porcine-brain-derived peptide soup that mimics several endogenous neurotrophic factors, with the best clinical signal in acute ischemic stroke.

Cerebrolysin is manufactured by EVER Neuro Pharma through controlled enzymatic hydrolysis of purified porcine brain proteins. The biologically active fraction contains peptide fragments smaller than 10 kilodaltons together with free amino acids in approximately a 25:75 ratio by mass [2]. The peptide fraction appears to act as a mimetic of endogenous neurotrophic factors. Mechanistic work has documented brain-derived neurotrophic factor (BDNF)-like and ciliary neurotrophic factor (CNTF)-like activity, stimulation of neurogenesis in the adult hippocampus in rodent models, reduction of excitotoxic calcium overload, and inhibition of calpain-mediated proteolysis after ischemic injury [2,4].

Cerebrolysin is hydrophilic, and its low-molecular-weight peptide fraction appears to cross the blood-brain barrier after parenteral dosing [2]. Pharmacokinetic data in the public literature are limited because the preparation is not a single molecular entity; plasma half-life cannot be meaningfully reported for the mixture.

Dose-response modeling from the CASTA trial (Cerebrolysin Acute Stroke Treatment in Asia, NCT00756249) and from the CARS-1 and CARS-2 ischemic stroke trials indicates that efficacy signals have concentrated at the 30 mL daily dose given for 10 to 21 days in patients with moderate to severe baseline National Institutes of Health Stroke Scale (NIHSS) scores [1,3].

In Alzheimer's dementia, the pivotal double-blind trials have used 10 mL and 30 mL daily intravenous doses over four-week cycles repeated two to four times per year, with cognitive outcomes measured on the ADAS-cog+ and CIBIC+ instruments [5]. Preclinical work in traumatic brain injury models has shown reductions in neuronal loss in hippocampal CA1 and CA3 after controlled cortical impact when Cerebrolysin is given within 24 hours of injury [6].

Cerebrolysin Dose Ranges in the Peer-Reviewed Literature

In short: clinical trials have used four dose tiers — 10, 20, 30, and 50 mL daily — across stroke, dementia, and TBI indications.

Cerebrolysin is supplied in glass ampules and vials at a fixed concentration of 215.2 mg/mL (peptide plus amino acid mass). Unlike lyophilized peptides, the product is already in solution and does not require reconstitution. Reported dose volumes in peer-reviewed clinical trials are shown below.

Across adult neurological indications, the literature effectively offers four dose tiers: 10 mL (the low-dose cognitive protocol), 20 mL (subacute rehabilitation), 30 mL (acute stroke, moderate TBI, and higher-dose dementia arms), and 50 mL (the high-dose TBI arm in CAPTAIN). Volumes above 50 mL per day are not supported by any trial reviewed here. Pediatric protocols scale by body weight in the 1 to 2 mL per 10 kg range and are confined to intramuscular administration [9].

The literature does not describe subcutaneous, sublingual, intranasal, or oral routes as clinically effective. Attempts at oral dosing would be expected to result in complete proteolytic degradation in the gastric and intestinal lumen.

Cerebrolysin Reconstitution: Math and Worked Examples

In short: Cerebrolysin is pre-dissolved at 215.2 mg/mL. You don't reconstitute — you draw, dilute into saline, and infuse.

Cerebrolysin does not require reconstitution. The product is supplied as a clear, amber-colored aqueous solution at a fixed concentration of 215.2 mg of total peptide/amino acid content per 1 mL. Clinicians and researchers draw directly from the ampule or multi-dose vial.

Two common vial formats appear in the literature:

• 10 mL ampule (2,152 mg total Cerebrolysin content)
• 30 mL multi-dose vial (6,456 mg total Cerebrolysin content; listed in the frontmatter as "1076 mg per 5 mL equivalent" for interoperability with other dosing pages, but practically delivered as a 30 mL ampule or vial)

For IV administration, the target daily volume is combined with 0.9% sodium chloride or 5% dextrose to yield a 100 to 250 mL infusion bag delivered over 15 to 60 minutes. A representative worked example:

• Target dose: 30 mL Cerebrolysin (≈6,456 mg total solids)
• Diluent: 100 mL 0.9% NaCl
• Final volume: 130 mL
• Infusion time: 30 minutes → 4.33 mL/min
• Concentration at infusion: 6,456 mg / 130 mL ≈ 49.7 mg/mL

For IM administration, up to 5 mL may be injected per site; larger daily volumes are split across multiple injection sites or delivered as IV. A 10 mL IM daily dose is typically split into two 5 mL injections, one per gluteal quadrant.

Because the product is pre-dissolved, "concentration" and "units on an insulin syringe" are not meaningful. The relevant measurements are the volume drawn and the diluent volume for IV preparation.

How Cerebrolysin Is Administered

In short: IV infusion is the dominant route in the trials, IM is the fallback when venous access is impractical.

The published clinical trials have used two parenteral routes. Intravenous infusion has been the dominant route in stroke, TBI, and dementia studies. The daily dose is diluted into 100 to 250 mL of isotonic saline or 5% dextrose and infused over 15 to 90 minutes through a peripheral IV line [1,3,5]. Slower infusions (60 to 90 minutes) have been preferred in elderly patients and in those with a history of cardiovascular instability. The product should not be mixed with amino acid solutions, balanced electrolyte solutions containing polyvalent cations, or lipid emulsions in the same line.

Intramuscular injection has been used where IV access is impractical, particularly in rural clinical settings, pediatric cerebral palsy rehabilitation, and chronic repeat-cycle dementia protocols [9]. Up to 5 mL may be injected per site. The ventrogluteal and dorsogluteal regions are preferred for adults; the vastus lateralis is preferred for pediatric patients. Volumes above 10 mL per day by IM route become impractical and are typically converted to IV.

Timing relative to meals, sleep, or exercise has not been systematically studied. Trial protocols have generally administered Cerebrolysin in the morning to allow observation for infusion-related adverse events during the treatment day.

For syringe selection, a 10 mL luer-lock syringe with a 21 or 22 gauge needle is standard for drawing from the ampule; the infusion is then transferred into the saline bag. Insulin syringes are not used with Cerebrolysin because the volumes exceed insulin-syringe capacity and the product is not a microdosed peptide.

Cerebrolysin Cycle Structure and Protocol Duration

In short: three cycle shapes dominate — a single 10–21-day acute course, a 4-week rehabilitation block, or 4 maintenance courses per year.

The published protocols use one of three cycle structures. Acute course: a single uninterrupted block of 10 to 21 consecutive daily infusions beginning as soon as possible after the index event (stroke, TBI). The CARS-2013 and CASTA trials both used 10 daily doses [1,3]. The CAPTAIN TBI program used 10 days of high-dose 50 mL followed by a 10-day taper at 10 mL [8]. Rehabilitation course: 5 days per week for 4 consecutive weeks, then a washout, as used in the VITAL vascular-dementia study [7]. Maintenance course: 4 cycles per year of 20 treatment days each in Alzheimer's disease, spaced at 3-month intervals [5].

Tolerance or tachyphylaxis has not been documented in the literature. Washout periods between cycles in the dementia trials were defined pragmatically (3 months) rather than pharmacologically. There is no evidence for indefinite continuous dosing; all controlled trials used defined cycles with off-drug intervals.

Published protocols do not describe dose titration. The full daily volume is delivered from day one, unlike hormone-modulating peptides that often ramp.

Cerebrolysin Side Effects and Safety Profile

In short: the trial safety database is reassuring but narrow — infusion-site warmth, flushing, and rare anaphylactoid reactions are the main flags.

Adverse events reported in the pooled clinical trial database include injection-site warmth, flushing, dizziness, headache, mild agitation during infusion, and transient elevations in hepatic transaminases [1,3,5]. Serious adverse events attributed to the drug have been uncommon. Anaphylactoid reactions have been rare but are specifically flagged in the European summary of product characteristics; porcine-derived biologic origin is the mechanistic basis for caution in patients with known protein allergies.

The CARS-2013 safety analysis reported no statistically significant difference in mortality, symptomatic intracranial hemorrhage, or serious adverse event rates versus placebo in acute stroke patients, including those receiving concurrent recombinant tissue plasminogen activator [1]. Hepatic and renal function monitoring is standard in registered jurisdictions.

Contraindications in the European label include known hypersensitivity to the product, severe renal impairment, and status epilepticus. Pregnancy and lactation are listed as contraindications on the basis of inadequate data rather than demonstrated harm. Drug interactions with monoamine oxidase inhibitors and with concurrent amino acid infusions have been noted.

Community self-report data are limited relative to the clinical trial database because Cerebrolysin requires parenteral administration and has not seen the same research-chem distribution as subcutaneous peptides. The primary safety database is the registration trial record, not community reporting.

Reports from Russian and Eastern European clinical practice describe rare cases of asymptomatic elevation in serum aminotransferases during extended maintenance cycles; these normalize after cycle completion and have not required drug discontinuation in the large majority of cases [5].

Because Cerebrolysin is porcine-derived, religious and cultural dietary restrictions are relevant for some patient populations. The manufacturer does not offer a non-porcine variant, and no synthetic or recombinant substitute has demonstrated equivalent clinical outcomes. Researchers designing protocols in populations where porcine origin is a concern should document informed consent specific to that issue. Thermal stability of the product degrades above 25°C; ampules should be stored below that threshold and protected from light.

Cerebrolysin Vendor Ratings: Who Publishes Lab Data at ≥99% Purity?

TriedRx aggregates publicly available third-party lab reports, batch-consistency disclosures, and reputation signals for vendors distributing Cerebrolysin ampules. Because Cerebrolysin is a mixture rather than a single molecule, the relevant quality question is whether vendors publish peptide-fraction profile data consistent with genuine EVER-manufactured product, along with endotoxin and sterility reports. We do not run the assays ourselves; we compile what vendors and independent testing groups publish and grade the disclosures against our transparency rubric.

See all Cerebrolysin vendors we've rated →

Related: Cerebrolysin Research Profile and Vendor Rankings

For the full research background, a review of the major stroke and dementia trials, and the manufacturer and regulatory history in Europe and Asia, see the TriedRx Cerebrolysin peptide profile. The profile covers neurotrophic mechanism, BDNF and CNTF mimetic activity, pharmacokinetic limitations, and a head-to-head evidence summary against other neurotrophic peptide mixtures.

References

1. Heiss WD, Brainin M, Bornstein NM, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PMID: 22282884.
2. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012;48(Suppl A):3-24. PMID: 22514803.
3. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-159. PMID: 26564102. NCT01215708.
4. Rockenstein E, Ubhi K, Pham E, et al. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease. J Neurosci Res. 2011;89(11):1812-1821. PMID: 21792886.
5. Gauthier S, Proano JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID: 25832905.
6. Zhang Y, Chopp M, Meng Y, et al. Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury. J Neurosurg. 2015;122(4):843-855. PMID: 25555079.
7. Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-318. PMID: 21576056.
8. Poon W, Vos P, Muresanu D, et al. Cerebrolysin for traumatic brain injury (CAPTAIN II): a multicenter, randomized, double-blind, placebo-controlled trial. CNS Neurol Disord Drug Targets. 2020;19(10):782-793. DOI: 10.2174/1871527319666201001110937.
9. Krasnoperov RA, Guekht AB. Observational cohort of Cerebrolysin in pediatric cerebral palsy rehabilitation. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8):41-47. PMID: 30160680.